Cells as vehicles for cancer gene therapy: The missing link between targeted vectors and systemic delivery?

Human Gene Therapy

Volumn 13, Issue 11, 2002, Pages 1263-1280

  Harrington, Kevin ^a,b   Alvarez Vallina, Luis ^c   Crittenden, Marka ^b   Gough, Michael ^b   Chong, Heung ^b   Diaz, Rosa Maria ^b   Vassaux, Georges ^d   Lemoine, Nicholas ^d   Vile, Richard ^b  

^a INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^b MAYO CLINIC   (United States)

^c HOSPITAL UNIVERSITARIO PUERTA DE HIERRO   (Spain)

^d IMPERIAL COLLEGE SCHOOL OF MEDICINE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOSINE DEAMINASE; DRUG VEHICLE; GANCICLOVIR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 2; MEMBRANE PROTEIN; RECOMBINANT DNA; THYMIDINE KINASE; VIRUS VECTOR;

ADOPTIVE IMMUNOTHERAPY; CANCER CELL; CANCER IMMUNOTHERAPY; CANCER LOCALIZATION; CELL ACTIVITY; CELL ISOLATION; CLINICAL TRIAL; GENE EXPRESSION; HUMAN; MACROPHAGE; MICROORGANISM; NONHUMAN; REVIEW; STEM CELL; T LYMPHOCYTE; VIRAL GENE DELIVERY SYSTEM; VIRUS GENOME; VIRUS REPLICATION;

CELL TRANSPLANTATION; DRUG DELIVERY SYSTEMS; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE TARGETING; GENE THERAPY; GENE TRANSFER TECHNIQUES; GENETIC ENGINEERING; GENETIC VECTORS; HUMANS; MODELS, BIOLOGICAL; NEOPLASMS; RETROVIRIDAE; VIRUS DISEASES;

EID: 0036376654     PISSN: 10430342     EISSN: None     Source Type: Journal    
DOI: 10.1089/104303402760128504     Document Type: Review

References (167)

1. Complementary adenoviral vectors for oncolysis
2. Replicative adenoviruses for cancer therapy
3. Blood clearance rates of adenovirus type 5 in mice
4. Adoptive transfer of in vitro-targeted, activated T lymphocytes results in total tumor regression
5. Pharmacological control of antigen responsiveness in genetically modified T lymphocytes
6. Pharmacologic suppression of target cell recognition by engineered T cells expressing chimeric T-cell receptors
7. Adoptive transfer of tumor cytotoxic macrophages generated in vitro from circulating blood monocytes: A new approach to cancer immunotherapy
8. Activated macrophages induce structural abnormalities of the T cell receptor-CD3 complex
9. Isolation of putative progenitor endothelial cells for angiogenesis
10. Bone marrow origin of endothelial progenitor cells responsible for postnatal vasculogenesis in physiological and pathological neovascularization
11. Impaired NK response of cancer patients to IFN-α but not to IL-2: Correlation with serum immunosuppressive acidic protein (IAP) and role of suppressor macrophage
12. 2 antibody
13. Use of activated natural killer cells for tumor immunotherapy in mouse and human
14. Fusogenic membrane glycoproteins as a novel class of genes for the local and immune-mediated control of tumor growth
15. An adenoviral vector regulated by hypoxia for the treatment of ischaemic disease and cancer
16. Recruitment of bone-marrow-derived cells by skeletal and cardiac muscle in adult dystrophic mdx mice
17. Turning brain into blood: A hematopoietic fate adopted by adult neural stem cells in vivo
18. Heat shock protein-peptide complexes, reconstituted in vitro, elicit peptide-specific cytotoxic T lymphocyte response and tumor immunity
19. Genetic re-targeting of T lymphocyte specificity
20. Involvement of inflammatory mediators in macrophage antitumor activity
21. Human tumor antigens recognized by T lymphocytes
22. Identification of tumor rejection antigens recognised by T lymphocytes
23. Cell therapy: Achievements and perspectives
24. Redirecting the complete T cell receptor/CD3 signaling machinery towards native antigen via modified T cell receptor
25. Embryonic stem cell-derived glial precursors: A source of myelinating transplants
26. Clostridial oncolysis in man
27. Engineering of macrophages to produce IFN-γ in response to hypoxia
28. Immunogenetic therapy of human melanoma utilizing autologous tumor cells transduced to secrete granulocyte-macrophage colony-stimulating factor
29. Signal integration by transcription-factor assemblies: Interactions of NF-AT1 and AP-1 on the IL-2 promoter
30. Tumor antigen-specific induction of transcriptionally targeted retroviral vectors from chimeric immune receptor-modified T cells
31. Readministration of adenovirus vector in nonhuman primate lungs by blockade of CD40-CD40 ligand interactions
32. Osteoclasts are required for bone tumors to grow and destroy bone
33. Use of carrier cells to deliver a replication-selective herpes simplex virus-1 mutant for the intraperitoneal therapy of epithelial ovarian cancer
34. In vivo gene transfer with retroviral vector-producer cells for treatment of experimental brain tumors
35. Strategies to adapt adenoviral vectors for targeted delivery
36. The development of conditionally replicative adenoviruses for cancer therapy
37. The case for therapeutic vaccines
38. Posttransplant adoptive immunotherapy with activated natural killer cells in patients with metastatic breast cancer
39. Exchange of viral promoter/enhancer elements with heterologous regulatory sequences generates targeted hybrid long terminal repeat vectors for gene therapy of melanoma
40. A lentiviral vector expressing a fusogenic glycoprotein for cancer gene therapy
41. The intriguing role of polymorphonuclear neutrophils in antitumor reactions
42. Functional characterization of adenoviral/retroviral chimeric vectors and their use for efficient screening of retroviral producer cell lines
43. In vitro immune blastogenesis during contact sensitivity in tumor-bearing mice. I. Description of progressive impairment and demonstration of splenic suppressor cells
44. Tumor-induced immune dysfunction: The macrophage connection
45. A transcriptional feedback loop for tissue-specific expression of highly cytotoxic genes which incorporates an immunostimulatory component
46. Oncolysis by clostridia. V. Transplanted tumors of the hamster
47. Specific activation and targeting of cytotoxic lymphocytes through chimeric single chains consisting of antibody-binding domains and the γ or ζ subunits of the immunoglobulin and T-cell receptors
48. Macrophage requirement for growth of a murine fibrosarcoma
49. The allogeneic response and tumor immunity
50. Regulation of macrophage cytokine production by phagocytosis of apoptotic and post-apoptotic cells
51. Stable in vivo transduction via a novel adenoviral/retroviral chimeric vector
52. Muscle regeneration by bone marrow-derived myogenic progenitors
53. The implications of angiogenesis for the biology and therapy of cancer metastasis
54. Recognition and destruction of neoplastic cells by activated macrophages: Discrimination of altered self
55. Antiangiogenic gene therapy
56. Angiogenesis research: From laboratory to clinic
57. Immunoprevention of cancer: Is the time ripe?
58. The "bystander effect": Tumor regression when a fraction of the tumor mass is genetically modified
59. Genetic capsid modifications allow efficient re-targeting of adeno-associated virus type 2
60. + cells as cellular vehicles for gene delivery into areas of angiogenesis in a rhesus model
61. Isolation and functional properties of murine hematopoietic stem cells that are replicating in vivo
62. Inducible gene expression systems for higher eukaryotic cells
63. Transcriptional activation by tetracyclines in mammalian cells
64. Generation and characterization of recombinant vascular targeting agents from hybridoma cell lines
65. Macrophages orchestrate the immune response to tumor cell death
66. Interferon-γ inhibits tumor antigen presentation by epidermal antigen-presenting cells
67. The macrophage: A novel system to deliver gene therapy to pathological hypoxia
68. Combined targeting of adenoviruses to integrins and epidermal growth factor receptors increases gene transfer into primary glioma cells and spheroids
69. Functional gene transfer from intracellular bacteria to mammalian cells
70. Dystrophin expression in the mdx mouse restored by stem cell transplantation
71. Molecular engineering of matrix-targeted retroviral vectors incorporating a surveillance function inherent in von Willebrand factor
72. Transcriptional control: An essential component of cancer gene therapy strategies?
73. An adenovirus E1A mutant that demonstrates potent and selective systemic anti-tumoral efficacy
74. Macrophages as regulators of immune responses against tumors
75. A chimeric receptor that selectively targets membrane-bound carcinoembryonic antigen (mCEA) in the presence of soluble CEA
76. Correlation of specific immune responses with survival in melanoma patients with distant metastases receiving polyvalent melanoma cell vaccine
77. Hepatic intra-arterial delivery of a retroviral vector expressing the cytosine deaminase gene, controlled by the CEA promoter and intraperitoneal treatment with 5-fluorocytosine suppresses growth of colorectal liver metastases
78. Gene therapy of metastatic cancer by in vivo retroviral gene targeting
79. Oral tolerization to adenoviral antigens permits long term gene expression using recombinant adenoviral vectors
80. T cell recognition of human tumors: Implications for molecular immunotherapy of cancer
81. Angiogenesis and vasculogenesis as therapeutic strategies for postnatal neovascularization
82. A tale of two trials: Selectively replicating herpesviruses for brain tumors
83. Replication-selective virotherapy for cancer: Biological principles, risk management and future directions
84. Tumor infiltration by adoptively transferred T cells is independent of immunologic specificity but requires down-regulation of L-selectin expression
85. Oxygen tension regulates the expression of angiogenesis factor by macrophages
86. A novel telomerase-specific gene therapy: Gene transfer of caspase-8 utilizing the human telomerase catalytic subunit gene promoter
87. Genetic targeting of an adenovirus vector via replacement of the fiber protein with the phage T4 fibritin
88. Association of macrophage infiltration with angiogenesis and prognosis in invasive breast carcinoma
89. Anaerobic bacteria as gene delivery system that is controlled by the tumor microenvironment
90. Impaired recruitment of bone-marrow-derived endothelial and hematopoietic precursor cells blocks tumor angiogenesis and growth
91. The origin and function of tumor-associated macrophages
92. Tumor immunogenicity is determined by the mechanism of cell death via induction of heat shock protein expression
93. Tumor eradication by adoptive transfer of cytotoxic T lymphocytes
94. Macrophage arginine metabolism and the inhibition or stimulation of cancer
95. Drug sensitivity ("suicide") genes for selective cancer chemotherapy
96. Prolongation of survival in metastatic melanoma after active specific immunotherapy with a new polyvalent melanoma vaccine
97. Oncolysis by clostridia. I. Activity of Clostridium butyricum (M-55) and other non-pathogenic clostridia against the Ehrlich sarcoma
98. Bystander-effect-mediated therapy of experimental brain tumor by genetically engineered tumor cells
99. Hypoxia down-regulates MCP-1 expression: Implications for macrophage distribution in tumors
100. Phase II trial of intratumoral administration of ONYX-015, a replication-selective adenovirus, in patients with refractory head and neck cancer
101. Gene therapy: Designer promoters for tumor targeting
102. Plasmoviruses: Nonviral/viral vectors for gene therapy
103. Macrophage infiltration and tumor progression
104. Radioresponsive recA promoter significantly increases TNFα production in recombinant clostridia after 2 Gy irradiation
105. Clinical Protocol: Gene therapy for the treatment of brain tumors using intra-tumoral transduction with the thymidine kinase gene and intravenous ganciclovir
106. Angiostatin: A novel angiogenesis inhibitor that mediates the suppression of metastases by a Lewis lung carcinoma
107. Endostatin: An endogenous inhibitor of angiogenesis and tumor growth
108. Circumventing adenovirus immune response to achieve long-term correction of genetic diseases
109. Alteration in IL-1 and arginase activity of tumor-associated macrophages: A role in the promotion of tumor growth
110. Paracrine cytokine adjuvants in cancer immunotherapy
111. Generation of high-titer retroviral vector-producing macrophages as vehicles for in vivo gene transfer
112. Targeted macrophage cytotoxicity using a non-replicative live vector expressing a tumor-specific single-chain variable region fragment
113. Tumor-targeted Salmonella as a novel anticancer vector
114. Vector development for cancer gene therapy
115. Cultured adherent cells from marrow can serve as long-lasting precursor cells for bone, cartilage, and lung in irradiated mice
116. Initial binding of murine leukemia virus particles to cells does not require specific Env-receptor interaction
117. Marrow stromal cells as stem cells for non-hematopoietic tissues
118. Summary of results and conclusions of the gene therapy of malignant brain tumors: Clinical study
119. In situ retroviral mediated gene transfer for the treatment of brain tumors in rats
120. Toxicity studies of retroviral-mediated gene transfer for the treatment of brain tumors
121. Therapy of malignant brain tumors by intratumoral implantation of retroviral vector-producing cells
122. Purification and ex vivo expansion of postnatal human marrow mesodermal progenitor cells
123. A targetable, injectable adenoviral vector for selective gene delivery to pulmonary endothelium in vivo
124. Activated natural killer cell tumor retention and cytokine production in colon tumor using a tissue-isolated model
125. Suicide gene expression induced in tumor cells transduced with recombinant adenoviral, retroviral and plasmid vectors containing the ERBB2 promoter
126. Mechanisms of angiogenesis
127. A humanized system for pharmacologic control of gene expression
128. Regulation of protein secretion through controlled aggregation in the endoplasmic reticulum
129. Hypoxia and angiogenesis in experimental tumor models: Therapeutic implications
130. Prostate attenuated replication competent adenovirus (ARCA) CN706: A selective cytotoxic for prostate-specific antigen-positive prostate cancer cells
131. Adoptive immunotherapy of cancer: Accomplishments and prospects
132. Immunotherapy of cancer by systemic administration of lymphoid cells plus interleukin-2
133. The immunotherapy and gene therapy of cancer
134. A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high-dose interleukin-2 alone
135. Use of tumor-infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma: Special report
136. Prospective randomised trial of high-dose interleukin-2 alone or in conjunction with lymphokine activated killer cells for the treatment of patients with advanced cancer
137. Replicating vectors for cancer therapy: A question of strategy
138. Replicating vectors for gene therapy of cancer: Risks, limitations and prospects
139. Modifying the host range properties of retroviral vectors
140. Myogenic expression of mesenchymal stem cells within myotubes of mdx mice in vitro and in vivo
141. Corpse clearance defines the meaning of cell death
142. Derivation of pluripotent stem cells from cultured human primordial germ cells
143. Evidence for circulating bone marrow-derived endothelial cells
144. Tumor angiogenesis: Hitting cancer where it hurts
145. Macrophages and angiogenesis
146. Use of preferentially replicating bacteria for the treatment of cancer
147. Sensitization of cells and retroviruses to human serum by (α1-3) galactosyltransferase
148. Oncolysis by clostridia. III. Effects of clostridia and chemotherapeutic agents on rodent tumors
149. Retroviruses
150. Gene therapy: Promises, problems and prospects
151. Vironcology: Not yet, but soon?
152. Retroviruses as vectors
153. Systemic gene therapy of murine melanoma using tissue specific expression of the HSVtk gene involves an immune component
154. Tissue specific gene expression from Mo-MLV retroviral vectors with hybrid LTRs containing the murine tyrosinase enhancer/promoter
155. Cancer gene therapy: Hard lessons and new courses
156. A T cell-independent antitumor response in mice with bone marrow cells retrovirally transduced with an antibody/Fc-γ chain chimeric receptor gene recognizing a human ovarian cancer antigen
157. Single chain Ig/γ gene-redirected human T lymphocytes produce cytokines, specifically lyse tumor cells, and recycle lytic capacity
158. Monitoring of antigen-specific cytolytic T lymphocytes in cancer patients receiving immunotherapy
159. Mutational analysis of the adeno-associated virus type 2 (AAV2) capsid gene and construction of AAV2 vectors with altered tropism
160. MHC-class I-restricted cytotoxic T lymphocytes to viral antigens destroy hepatocytes in mice infected with E1-deleted recombinant adenoviruses
161. Cellular immunity to viral antigens limits E1-deleted adenoviruses for gene therapy
162. Regulated delivery of therapeutic proteins after in vivo somatic cell gene transfer
163. Melanocyte destruction after antigen-specific immunotherapy of melanoma: Direct evidence of t cell-mediated vitiligo
164. In vivo tracking of tumor-specific T cells
165. A new regulatory region of the IL-2 locus that confers position-independent transgene expression